In the United States, prescription drug prices are not only among the highest in the world—they’re soaring to levels that defy logic and morality.
Behind these figures is a carefully orchestrated system that prizes profits over patients, with pharmaceutical patents and aggressive marketing at the heart of the problem. Solving the US Drug Conundrum by André Wencker and Pascal Orliac pulls back the curtain on this industry-wide manipulation, offering readers a sharp, data-driven, and essential wake-up call.
At the core of the U.S. drug pricing issue is the power of patents. Pharmaceutical patents were originally intended to reward innovation by granting companies exclusive rights to market a drug for 20 years. However, as this book expertly lays out, that 20-year term is not what it seems. Drug companies spend an average of 8.6 years navigating clinical trials and regulatory hurdles before a product even hits the shelves. This means the real window for market exclusivity is significantly shorter, and that’s where the manipulation begins.
Rather than accepting the limited time left to profit, many pharmaceutical firms employ legal and regulatory maneuvers such as Supplementary Protection Certificates (SPCs), ever greening, patent thickets, and loophole exploitation. These methods allow companies to prolong their monopoly far beyond the original 20 years, effectively blocking generic competition and keeping prices inflated. Solving the US Drug Conundrum thoroughly dissects these tactics, illustrating how what was intended to protect innovation has been repurposed to suppress competition and extract value from patients and taxpayers.
But patent manipulation is only part of the story. Wencker and Orliac go deeper to expose another hidden mechanism that sustains the pharmaceutical monopoly: skyrocketing marketing expenditures. As patent expiration approaches, pharmaceutical companies invest vast sums—often in the hundreds of millions annually—into direct-to-consumer advertising and physician-targeted promotions.
The United States is one of only two countries in the world that allows direct-to-consumer advertising (DTCA) for prescription drugs. As revealed in the book, this regulatory leniency has transformed media spaces into battlegrounds for pharmaceutical giants. Ads flood television and digital platforms with emotionally charged, persuasive campaigns that build brand loyalty and discourage patients from choosing lower-cost generic alternatives.
One standout case discussed is AbbVie’s Humira, for which the company reportedly spent over $500 million per year on advertising, ensuring brand dominance well beyond its patent life. Simultaneously, pharmaceutical firms target physicians with lavish incentives, from speaking fees and sponsored conferences to research grants. These tactics reinforce prescribing patterns that favor brand-name drugs, even when generics are equally effective.
Together, prolonged patents and massive marketing budgets create a powerful, artificial monopoly. The result? High costs, limited access, and an overstretched healthcare system are buckling under the weight of inflated pharmaceutical spending. Solving the US Drug Conundrum does not merely describe these issues; it connects them to systemic failures, including the deeply entrenched phenomenon of regulatory capture, where regulatory agencies are influenced or even co-opted by the very industries they are meant to oversee.
The authors also highlight chilling statistics: in one of the world’s wealthiest nations, 10,000 people die annually from a lack of access to insulin, and 100,000 lose limbs, largely due to affordability barriers. These are not isolated incidents; they’re the symptoms of a deeply broken system.
In a striking moment of real-world resonance, the book’s release followed shortly after the tragic killing of UHC CEO Mike Thompson—an event that sparked an unexpected public outcry. What was startling was not just the tragedy, but the tidal wave of outrage directed at the U.S. health insurance system itself.
That’s why Solving the US Drug Conundrum is more than a book. It’s a blueprint for reform and a must-read for anyone who believes that affordable healthcare is a human right, not a privilege. The authors go beyond criticism, offering actionable solutions rooted in successful global practices and recent U.S. state-level reforms, most notably advocating for a constitutional Right to Healthcare and the adoption of Reference-Based Pricing (RBP) to import drug prices aligned with international benchmarks.
